By MICHAEL J. DE LA MERCED
Valeant said that it would increase the amount of cash that it would pay by $10 a share, to $58.30 per Allergan share. It will also offered up to $25 a share in additional payouts, if Allergan’s Darpin treatment hits certain performance thresholds.
Published: May 28, 2014 at 4:00AM
from NYT Business Day http://ift.tt/1kKe0Jb
via IFTTT
from WordPress http://ift.tt/SPiJPw
No comments:
Post a Comment